Skip to main content

Member Log In

Please do not use a Yahoo email for your account. If you are using one, change it now.

Forgot your password?

Latest News

East Meets West - ESCP's first Global Reach webinar announced

10 July 2020

ESCP's Global Reach Committee is delighted to announce its first webinar which will broadcast on Friday 24 July 2020.

New guidelines for the management of diverticular disease of the colon

Johannes Schultz, Eva Angenete, Zoe Garoufalia and Stephanie Breukink

9 July 2020

Interview by Zoe Garoufalia. Introduction by the authors Johannes Schultz and Eva Angenete.

Desmoid tumours in familial adenomatous polyposis and what every colorectal surgeon should know - snapshot interview with Gabriela Möslein

Vittoria Bellato and Gabriela Möslein

8 July 2020

Interview by Vittoria Bellato. Professor Gabriela Möslein is ESCP's General Secretary, Chair of the EHTG (European Hereditary Tumour Group) and Director of the Centre for Hereditary Tumours at Bethesda Hospital in Germany. She has dedicated her professional focus towards hereditary colorectal cancer both as a researcher and scientific communicator and is acknowledged worldwide for her contribution and expertise.

Pathophysiology of MSI: what the surgeon needs to know

Gloria Zaffaroni, Miguel Cunha and Gabriela Möslein

3 July 2020

A paper and visual abstract on microsatellite instability by Gloria Zaffaroni, Miguel Cunha and Gabriela Möslein.

Insights from the Prospective Lynch Syndrome Database: an Introduction by Dr Toni Seppälä

Zoe Garoufalia, Gloria Zaffaroni and Toni Seppälä

25 June 2020

Interview by Zoe Garoufalia and Gloria Zaffaroni. Lynch syndrome is characterised by predisposition to colorectal, endometrial, and other cancers, and is caused by autosomal dominant inherited pathogenic variants affecting the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2. It is probably the most common predisposition to cancer. Despite its high estimated prevalence, up until now, there were no reliable long term data of MMR variant carriers in order to plan their treatment according to evidence-based medicine principles.